HEDGEHOG PATHWAY IN THE PATHOGENESIS OF MULTIPLE MYELOMA
S. Blotta , S. Molica, J. Jakubikova, T. Calimeri, F. Morabito, N. Amodio, A.M. Roccaro, M. Dorsch, P. Tagliaferri, P. Tassone, K.C. Anderson, N.C. Munshi
Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts, USA; University Magna Graecia and Cancer Center, Catanzaro, Italy; Department of Hematology and Oncology Pugliese-Ciaccio Hospital, Catanzaro, Italy; Department of Tumor Immunology and VVCE CeXignal, Bratislava, Slovak Republic; Hematology Unit, Cosenza Hospital, Cosenza, Italy; Novartis Institute for BioMedical Research, Cambridge, Boston, MA

90Y-IBRITUMOMAB TREATMENT FOR RELAPSED AND/OR REFRACTORY B CELL TYPE NON-HODGKINS LYMPHOMA. MULTIINSTITUTIONAL ARGENTINIAN STUDY
R.E. Cacchione , J.C Dupont, J.C. Milone, J.A. Bordone, G. Garay, M. Castro-Rios, M. Labstrebner, S. Rudoy, H. Kupitzki, L. Palmer, F. Bezares
Hematology, Argentinian Study Groupe, Buenos Aires, Capital Federal, Argentina, 1431

INSIGHTS INTO ACUTE MYELOID LEUKEMIA VIA SINGLE CELL NETWORK PROFILING: TOWARDS IMPROVED CLASSIFICATION AND THERAPEUTIC SELECTION
A. Cesano
Nodality Inc., South San Francisco, CA, USA

GLYOXALASE-I IS A NOVEL TARGET AGAINST BCR-ABL+ LEUKEMIC CELLS ACQUIRING STEM-LIKE CHARACTERISTICS IN A HYPOXIC ENVIRONMENT
T. Maekawa, M. Takeuchi, E. Ashihara, S. Kimura
Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto & Department of Hematology/Oncology, Faculty of Medicine, Saga University, Saga, Japan

PROGNOSTIC FACTORS OF SURVIVAL TIME AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IN ACUTE LEUKEMIA PATIENTS; USING AND COMPARISON PARAMETRIC AND SEMI-PARAMETRIC SURVIVAL MODELS
K. Sayehmiri, K. Alimoghaddam
Ilam University of Medical Sciences; Hematology- Oncology and Stem Cell Transplantation Research Center, Tehran University / Medical Sciences, Iran